Streetbeat News

PRDS

Pardes Biosciences Inc

pardesbio.com

Employees

Industry

Research and Development in Biotechnology

better chemistry committed to the world's biggest problems

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

MediPacific is making a tender offer for Pardes Biosciences at $2.13 per share, plus one Contingent Value Right per share. The offer is subject to acceptance by Pardes Biosciences shareholders.

Portfolio Pulse from Happy Mohamed

August 28, 2023 | 3:34 pm

MediPacific has reported an additional price per share and an extension of the expiration date for its tender offer for Pardes Biosciences shares. The total cash amount that the purchaser will pay according to the terms of the offer and the merger agreement is $2.13 per share.

Portfolio Pulse from Benzinga Newsdesk

August 17, 2023 | 9:45 pm

JMP Securities analyst Roy Buchanan has downgraded Pardes Biosciences (NASDAQ:PRDS) from Market Outperform to Market Perform.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:22 am

Several stocks experienced significant movement in Monday's mid-day session. ProMIS Neurosciences, Acumen Pharmaceuticals, BridgeBio Pharma, Lixte Biotechnology Holdings, and Healthcare Triangle were among the top gainers, with shares jumping due to various reasons such as positive preclinical data, successful Phase 1 studies, and strong financial results. On the other hand, Novan, ViewRay, UTime Limited, Jiuzi Holdings, and BYND Cannasoft Enterprises were among the biggest losers, with shares falling due to factors such as asset sales, Chapter 11 filings, and direct offerings.

Portfolio Pulse from Lisa Levin

July 17, 2023 | 5:14 pm

MediPacific has agreed to acquire Pardes Biosciences Inc (NASDAQ:PRDS) for $2.02 to $2.19 per share in cash, along with contingent value rights associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property. The acquisition is expected to close in the third quarter.

Portfolio Pulse from Adam Eckert

July 17, 2023 | 1:25 pm

MediPacific has agreed to acquire Pardes Biosciences for $2.02-$2.19 per share in cash plus contingent value rights. This has led to a rise in Pardes Biosciences' share price.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:54 am

Pardes Biosciences has agreed to be acquired by MediPacific, Inc. for between $2.02 and $2.19 in cash per share, plus contingent value rights. The deal is subject to shareholder approval.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 11:01 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.